Immune booster shows promise for rare anemia
NCT ID NCT02389231
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This early-phase trial tested a low dose of interleukin-2 (IL-2) in 2 adults with warm autoimmune hemolytic anemia that did not improve with standard steroids. The goal was to see if IL-2 could increase a specific type of immune cell (CD8 Tregs) that may help control the disease. The study focused on safety and changes in blood markers, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Bordeaux Hôpital Haut Lévêque
Pessac, Aquitaine, 33604, France
Conditions
Explore the condition pages connected to this study.